In the light of scarce resources to be allocated for cancer care and a steady stream of costly innovations in all modalities applied to treat cancer, particle therapy needs to demonstrate its cost-utility balance to allow its positioning in the context of competing modalities. In the continuous evolving particle therapy landscape, the timely availability of appropriate economic data is crucial.
from Imaging via alkiviadis.1961 on Inoreader http://bit.ly/2GUQg5a
Πέμπτη 29 Μαρτίου 2018
Economic data for particle therapy: Dealing with different needs in a heterogeneous landscape
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nL9dMr via IFTTT
-
by Demin Li, Carol Bentley, Jenna Yates, Maryam Salimi, Jenny Greig, Sarah Wiblin, Tasneem Hassanali, Alison H. Banham Therapeutic monoclon...
-
Background Although pneumonia is a leading cause of death in New York City (NYC), limited data exist about the settings in which pneumonia ...
-
Vol.30 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nItCSB via IFTTT
-
Summary We tested whether prophylactic droperidol and ondansetron, in combination with a moderate dose of dexamethasone, were equally effe...
-
Abstract Background Head and neck extirpations requiring reconstruction are challenging surgeries with high postoperative complication r...
-
Web version of a book about Subversion. Work in progress, however already very complete. The book should be published by O'Reilly and As...
-
ACS Nano DOI: 10.1021/acsnano.6b08567 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oNpdhD via...
-
Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea syndrome (OSA) are both highly prevalent, which implies that both d...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου